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Introduction Results
Bladder cancer is the fifth most com m on cancer in men Patient characteristics 
and the seventh in women. C om bination  regimens con­
taining cisplatin have produced response rates in 50% - There were 15 males and 4 females with a median age of 
70% of patients with complete responses in 2G%-30% [1]. 64 years (range 54-77 years), and a median WHO perfor- 
Lobaplatin (1,2-diamminomethylcyclobutane-plati- mance status 1 (0-2). The primary site was bladder in 16 
num (II) lactate, D-19466) is a th ird  generation plati- patients, renal pelvis in two, renal pelvis + ureter in one. 
num analogue. It is water soluble and stable and may not Twelve patients had prior chemotherapy including cis- 
be cross-resistant with cisplatin [2, 3], A favorable tox- platin or earboplatin in seven, and three had prior RT. 
icity profile and similar efficacy to cisplatin stimulated a Measurable disease sites were the primary tumor in
phase II study in patients with advanced urothelial tract
tumors.
seven patients, lymph nodes in 21, lung in seven, liver in 
four and bone in two.
Patients and methods
Patients with histologically proven bidimension ally measurable meta­
static or locally advanced TCC of the urinary tract were eligible. 
Patients with unresected carcinoma of the ureter or renal pelvis were 
excluded, Patients may have had only one prior chemotherapy regi­
men, WHO performance status <2, age <75 years, creatinine clear­
ance 52=40 ml/min, bilirubin <35 micromol/1, granulocytes >2000 
cells/mm\ platelets > 125,000 cells/mm\ and clinically normal audi­
tory function.
Lobaplatin was supplied by ASTA Medica, Germany, and given at 
50 m g/nr i.v. every three weeks, Drug was continued until develop­
ment of progressive disease. Dose modification to 60 m g/n r  (nadir 
>50,000 and granulocytes >1,000) or dose reduction lo 40 mg/m2 
(treatment day platelets < 100,000 or granulocytes < 1,500) were per­
mitted in subsequent cycles.
For a creatinine clearance >40 ml/min, 100% of the dose was 
given, For <40 ml/min, lobaplatin was withheld. Patients were evalu­
able for response if they had received at least two treatment courses. 
However, those patients progressive after one course were considered 
as in progression. Response was evaluated after every two cycles of 
treatment. À partial response was defined as at least a 50% reduction 
of the bidimensionully measurable disease parameters, determined by 
two observations not less than four weeks apart.
The protocol was conducted according to the Helsinki declaration. 
Written or oral informed consent was attained according to the guide­
lines in each participating institution.
Response
Twenty-two patients were entered in the trial, of whom 
three were ineligible. Two because they had received two 
previous lines of chemotherapy, and one because the 
performance status was 3 and no creatinine clearance 
was available prior to entry Therefore, 19 patients were 
eligible. Two patients were inevaluable for response. One 
patient never received lobaplatin due to a myocardial 
infarction. Another patient had an early death caused by 
a CVA due to thrombosis.
The total number of cycles delivered to 18 patients
was 50. The median number of cycles administered was
2 (range 0 -6 cycles). O f 17 evaluable patients, two had a 
confirmed partial response, one in lymph nodes and the 
other in the skin for 27+ weeks and 20 weeks. Five 
patients were stable. One patient, with a creatinine clear­
ance of 48 and no prior treatment had a PR in retroper­
itoneal lymph nodes and bladder. He was hospitalized 
with a platelet count of 5,000 cells/mm3 after two cycles 
of lobaplatin. He was subsequently treated with M-VAC, 
without a repeat CAT scan at one month, and was 
considered as stable. Thus, 2 of 17 (12%; 95% Cl 
0%-30%) patients had a PR and 5 of 17 (29%; 95% Cl 
8%~50%) had stable disease. O f note, patients who
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Tabie I. Hematological toxicity.
WHO grade 0 {%) 1 (%) 2 (%) 3 (%) 4 (%)
White blood cells 3(16) 1 (6) 4 (22) 9 (50) 1 (6)
Granulocytes 3(17) 4 (22) 6(33) 5(28)
Platelets 1 (6) 1 (6) 4(22) 12(67)
Hemoglobin 2(11) 2(11) 3(16) 8(46) 3(16)
Table 2. Non hematologic side effects.
WHO grade 0 (%) 1 (%) 2 (%) 3 (%) 4 (%)
Nausea/vomiting 6(33) 3(17) 4(22) 4(22) 1 (6)
Diarrhea 16(89) 1 (6) 1(6)
Liver 15(83) 1 (6) 1(6)
Renal 16(89) 2(11)
Pulmonary 17(94) 1 (6)
Drug fever 14(78) 2(11) 1 (6) 1 (6)
Infection 16(89) 2(11)
Mucositis 15(83) 1 (6) 2(11)
Neurotoxicity 13 (71) 1(6) 3(17) 1 (6)
Ototoxicity 17(94) 1 (6)
ovarian cancer [7], in testis cancer, and in esophageal 
tumors [8].
The present study was closed due to prohibitive 
thrombocytopenia, although 2 of the 17 (12%) evaluable 
patients obtained a PR. Of note, neither of these two 
patients had had prior carboplatin or cisplatin. The 
majority of patients entered into this study had therapy 
with a prior analogue. In a brief report o f five patients 
with advanced TCC, treated with the combination of 
lobaplatin, methotrexate and vinblastine (LMV), the 
toxicity profile was acceptable [9].
The toxicity profile of lobaplatin resembles that of 
carboplatin, and consists of thrombocytopenia and leu­
kopenia. In the present study, it was impossible to 
correlate creatinine clearance to thrombocytopenia. In 
retrospect, this trial should not have been conducted in 
this pre-treated patient population and should have 
excluded patients with low creatinine clearance upon 
entry. In conclusion, lobaplatin showed limited activity 
in this patient population.
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